Biomarker and Multidisciplinary Predialysis Education in Chronic Kidney Disease Patients
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Chronic Kidney Disease
- Sponsor
- Chang Gung Memorial Hospital
- Enrollment
- 8000
- Locations
- 1
- Primary Endpoint
- difference of US dollars
- Status
- Recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
CKD is a global endemic disease with increased comorbidities and mortality. The prevalence and the incidence of the end-stage renal disease (ESRD) are extremely high in Taiwan. Early diagnosis of disease and proper management remain challenging. The aims of this study are:
- Explore risk factors associated with CKD
- Establish multidisciplinary care model for CKD patients
- Development cost-effective clinical care pathway for CKD
- Provide bio-specimen repository for future study
Detailed Description
CKD is a global endemic disease with increased comorbidities and mortality. The prevalence and the incidence of the end-stage renal disease (ESRD) are extremely high in Taiwan. Early diagnosis of disease and proper management remain challenging. The aims of this study are: 1. Explore risk factors associated with CKD: demographic, social and genetics factors 2. Establish multidisciplinary care model for CKD patients 3. Development cost-effective clinical care pathway for CKD 4. Provide bio-specimen repository for future study: serum, PBMC, urine and stool
Investigators
I Wen Wu, MD
Principal Investigator
Chang Gung Memorial Hospital
Eligibility Criteria
Inclusion Criteria
- •Subjects visiting outpatient clinics of nephrology of Chang Gung Memorial Hospital
Exclusion Criteria
- •Patient receiving dialysis or transplantation
- •Unwilling to participate
Outcomes
Primary Outcomes
difference of US dollars
Time Frame: through study completion, every 1 year
differences of US dollars of medical care (out patients and inpatients service fees) between groups
percentage (%)
Time Frame: through study completion, every 1 year
percentage of patients with new CKD, starting dialysis treatments, cardiovascular event or mortality
Secondary Outcomes
- fold changes of microRNA(through study completion, every 1 year)
- fold changes of proteins(through study completion, every 1 year)